- Home
- MRSN vs CPBI Comparison
MRSN vs CPBI Comparison
Compare MRSN & CPBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRSN
- CPBI
- Stock Information
- Founded
- MRSN 2001
- CPBI 2023
- Country
- MRSN United States
- CPBI United States
- Employees
- MRSN N/A
- CPBI N/A
- Industry
- MRSN Biotechnology: Pharmaceutical Preparations
- CPBI
- Sector
- MRSN Health Care
- CPBI
- Exchange
- MRSN Nasdaq
- CPBI Nasdaq
- Market Cap
- MRSN 71.9M
- CPBI 58.0M
- IPO Year
- MRSN 2017
- CPBI N/A
- Fundamental
- Price
- MRSN $0.34
- CPBI $14.92
- Analyst Decision
- MRSN Buy
- CPBI
- Analyst Count
- MRSN 3
- CPBI 0
- Target Price
- MRSN $4.00
- CPBI N/A
- AVG Volume (30 Days)
- MRSN 3.1M
- CPBI 3.8K
- Earning Date
- MRSN 03-03-2025
- CPBI 01-01-0001
- Dividend Yield
- MRSN N/A
- CPBI N/A
- EPS Growth
- MRSN N/A
- CPBI 29.70
- EPS
- MRSN N/A
- CPBI 1.62
- Revenue
- MRSN $40,497,000.00
- CPBI $18,546,000.00
- Revenue This Year
- MRSN N/A
- CPBI N/A
- Revenue Next Year
- MRSN N/A
- CPBI N/A
- P/E Ratio
- MRSN N/A
- CPBI $9.26
- Revenue Growth
- MRSN 9.88
- CPBI 13.73
- 52 Week Low
- MRSN $0.34
- CPBI $9.96
- 52 Week High
- MRSN $4.64
- CPBI $15.50
- Technical
- Relative Strength Index (RSI)
- MRSN 29.11
- CPBI 54.39
- Support Level
- MRSN $0.41
- CPBI $14.80
- Resistance Level
- MRSN $0.42
- CPBI $14.97
- Average True Range (ATR)
- MRSN 0.04
- CPBI 0.10
- MACD
- MRSN -0.00
- CPBI 0.01
- Stochastic Oscillator
- MRSN 3.43
- CPBI 72.41
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.
About CPBI Central Plains Bancshares Inc.
Central Plains Bancshares Inc operates as the bank holding company for Home Federal Savings and Loan Association of Grand Island that provides mortgage, consumer, commercial real estate, and commercial loans, The bank business consists primarily of accepting deposits from the general public and investing those deposits, together with funds generated from operations, in one- to four-family residential mortgage loans secured by properties located in our primary market area, as well as commercial real estate loans.